Nymox studies fail
November 03, 2014 at 12:11 PM EST
Nymox Pharmaceutical Corp. (Nasdaq: NYMX) reported disappointing results from two Phase 3 studies of NX-1207. Shares of the biopharmaceutical collapsed $4.22 to $0.92.
Nymox studies failNovember 03, 2014 at 12:11 PM EST
Nymox Pharmaceutical Corp. (Nasdaq: NYMX) reported disappointing results from two Phase 3 studies of NX-1207. Shares of the biopharmaceutical collapsed $4.22 to $0.92.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|